Cargando…

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Leary, Connor, Gasper, Harry, Sahin, Katherine B., Tang, Ming, Kulasinghe, Arutha, Adams, Mark N., Richard, Derek J., O’Byrne, Ken J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600164/
https://www.ncbi.nlm.nih.gov/pubmed/32992872
http://dx.doi.org/10.3390/ph13100273
_version_ 1783603070154833920
author O’Leary, Connor
Gasper, Harry
Sahin, Katherine B.
Tang, Ming
Kulasinghe, Arutha
Adams, Mark N.
Richard, Derek J.
O’Byrne, Ken J.
author_facet O’Leary, Connor
Gasper, Harry
Sahin, Katherine B.
Tang, Ming
Kulasinghe, Arutha
Adams, Mark N.
Richard, Derek J.
O’Byrne, Ken J.
author_sort O’Leary, Connor
collection PubMed
description Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Patients with advanced EGFR-mutant NSCLC have a variety of EGFR-targeting agents available proven to treat their disease. This has led to superior patient outcomes when used as a monotherapy over traditional cytotoxic systemic therapy. Attempts at combining EGFR agents with other anticancer systemic treatment options, such as chemotherapy, antiangiogenic agents, and immunotherapy, have shown varied outcomes. Currently, no specific combination stands out to cause a shift away from the use of single-agent EGFR inhibitors in the first-line setting. Similarly, adjuvant EGFR inhibitors, are yet to significantly add to patient overall survival if used at earlier timepoints in the disease course. Liquid biopsy is an evolving technology with potential promise of being incorporated into the management paradigm of this disease. Data are emerging to suggest that this technique may be capable of identifying early resistance mechanisms and consequential disease progression on the basis of the analysis of blood-based circulating tumor cells.
format Online
Article
Text
id pubmed-7600164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76001642020-11-01 Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC) O’Leary, Connor Gasper, Harry Sahin, Katherine B. Tang, Ming Kulasinghe, Arutha Adams, Mark N. Richard, Derek J. O’Byrne, Ken J. Pharmaceuticals (Basel) Review Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Patients with advanced EGFR-mutant NSCLC have a variety of EGFR-targeting agents available proven to treat their disease. This has led to superior patient outcomes when used as a monotherapy over traditional cytotoxic systemic therapy. Attempts at combining EGFR agents with other anticancer systemic treatment options, such as chemotherapy, antiangiogenic agents, and immunotherapy, have shown varied outcomes. Currently, no specific combination stands out to cause a shift away from the use of single-agent EGFR inhibitors in the first-line setting. Similarly, adjuvant EGFR inhibitors, are yet to significantly add to patient overall survival if used at earlier timepoints in the disease course. Liquid biopsy is an evolving technology with potential promise of being incorporated into the management paradigm of this disease. Data are emerging to suggest that this technique may be capable of identifying early resistance mechanisms and consequential disease progression on the basis of the analysis of blood-based circulating tumor cells. MDPI 2020-09-25 /pmc/articles/PMC7600164/ /pubmed/32992872 http://dx.doi.org/10.3390/ph13100273 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
O’Leary, Connor
Gasper, Harry
Sahin, Katherine B.
Tang, Ming
Kulasinghe, Arutha
Adams, Mark N.
Richard, Derek J.
O’Byrne, Ken J.
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title_full Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title_fullStr Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title_full_unstemmed Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title_short Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
title_sort epidermal growth factor receptor (egfr)-mutated non-small-cell lung cancer (nsclc)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600164/
https://www.ncbi.nlm.nih.gov/pubmed/32992872
http://dx.doi.org/10.3390/ph13100273
work_keys_str_mv AT olearyconnor epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT gasperharry epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT sahinkatherineb epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT tangming epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT kulasinghearutha epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT adamsmarkn epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT richardderekj epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc
AT obyrnekenj epidermalgrowthfactorreceptoregfrmutatednonsmallcelllungcancernsclc